Differential p53, p21, mdm2 and Rb regulation in glioma cell lines that overexpress wild-type p53

International Journal of Oncology

Volumn 13, Issue 2, 1998, Pages 213-216

  Pykett, Mark J ^a   Azzam, Edouard ^a   Dahlberg, William ^a   Little, John B ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Gliomas; Irradiation; mdm2; p21; p53; Rb

Indexed keywords

PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; GENE CONTROL; GENE MUTATION; GENE OVEREXPRESSION; GLIOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 0031849622     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.2.213     Document Type: Article

References (32)

1. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
2. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
3. Anker L, Ohgaki H, Ludeke BI, Hermann HD, Kleihaus P and Westphal M: p53 protein accumulation and gene mutations in human gliomacell lines. Int J Cancer 55: 982-987, 1991.
4. MacGeoch C, Barnes DM, Newton JA, Mohammed SV, Ng M, Bishop DT and Spurr N: p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers 11: 239-250, 1991.
5. Rubio M, von Deimling A, Yandell DW, Wiestler OD, Gusella JF and Louis DN: Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 53: 3465-3467, 1993.
6. FultS D, Brockmeyer D, Tullous MW, Pedone CA and Cawthon RM: p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astocytoma progression. Cancer Res 52: 674-679, 1992.
7. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavenee W and Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumor prosression. Nature 355: 846-847, 1992.
8. Del Arco A, Garcia J, Arribas C, Barrio R, Blazquez MG, Izquierdo JM and Izquierdo M: Timing of p53 mutations during astrocytoma tumorigenesis. Hum Mol Genet 2: 1687-1690, 1993.
9. Van Mier EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang H-JS, Friedmann T, De Tribolet N and Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 469-652, 1994.
10. Von Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chamders AF and Cairncross JGP: p53 mutation, expression and DNA ploidy in evolving gliomas: evidence for two pathways of prosression. J Natl Cancer Inst 86: 1011-1017, 1994.
11. Mercer WE, Shields MT, Amin M, Suave GJ, Appella E, Romano JW and Ullrich SJ: Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87: 6166-6170, 1990.
12. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E and Fisher PB: Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21 WAF1/CIP1 expression in the absence of p53. Oncogene 9: 3397-3406, 1994.
13. Steinman RA, Iro A, Huffman B, Liebermann DA and El-Houseni M: Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 9: 3389-3396, 1994.
14. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D and Lassar AB: Correlation of terminated cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267: 1018-1021, 1995.
15. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW and Elledge SJ: p53-independent expression of p21 Cip1 in muscle and other terminally differentiating cells. Science 267: 1024-1027, 1995.
16. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telansiectasia. Cell 71:587-597, 1992.
17. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7498, 1992.
18. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M: Wild-type p53 induces apoptosis of myeloid Ieukaemic cell that is inhibited by Interleukin 6. Nature 352: 345-347, 1991.
19. Shaw P, Bovey R, Tardy S, Sahli T, Sordat B and Costa J: Induction of apoptosis by wild-type p53 in a human colontumor-derived cell line. Proc Natl Acad Sci USA 91: 9238-9242, 1992.
20. Pykett MJ, Murphy M, Harnish P and George DL: The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts. Hum Mol Genet 3: 559-564, 1994.
21. Jung JM, Li H, Kobayashi T, Kyritsis AP, Langford LA, Bruner JM, Levin VA and Zhang W: Inhibition of human glioblastoma cell growth by WAF1/CIP1 can be attenuated by mutant p53. Cell Growth Differ 6: 909-913, 1995.
22. Matsumoto H, Shimura M, Omatsu T, Okaichi K, Majima H and Ohnishi T: p53 proteins accumulated by heat stress associate with heat shock proteins HSP72/HSC73 in human glioblastoma cell lines. Cancer Lett 87: 39-46, 1994.
23. Reifenberger G, Liu L, Ichimura K, Schmidt EE and Collins VP: Amplification and over-expression of the MDM2 gene in a subset of malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739, 1993.
24. Werness BA, Levine AJ and Howley PM: Association of human papillomavirus types 16 and 18 with p53. Science 248: 76-79, 1990.
25. Momand J, Zambeyyi GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
26. Oliner JD, Kinzler KW, Melzer PS, George DL and Vogelstein B: Amplitication of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992.
27. Cordon-Cardo C, Latres E, Drobnijak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF and Levine AJ: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799, 1994.
28. Li C-Y, Nagasawa H, Dahlberg W and Little JB: Diminished capacity for p53 in mediating a radiation induced G1 arrest in established human tumor cell lines. Oncogene 11: 1185-1192, 1995.
29. Lehman TA, Bennett WP, Metcalf RA, Reddel R, Walsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Apella E, Testa JR, Gerwin BI and Harris CC: p53 mutations, ras mutations and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 51: 4090-4096, 1991.
30. Thompson AM, Anderson TJ, Condie A, Prosser J, Chettyn U, Carter DC, Evans HJ and Steel CM: p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathologic paramaters. Int J Cancer 50: 528-532, 1992.
31. Lu X, Burbridge SA, Griffin S and Smith HM: Discordance between accumulated p53 protein levels and its transcriptional activity in response to u.v. radiation. Oncogene 12: 413-418, 1996.
32. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell AA and Yandell DW: Ovarian, peritoneal and endometrial serous carcinomas: clonal origin of multifocal disease. Proc Natl Acad Sci USA 90: 4961-4965, 1993.